Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis

ConclusionWe present that use of DMT in POMS varies over the observed period concurrently with the availability of disease modifying drugs with progressive use of oral and high-efficacy therapies.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research